Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts

Table 2 Clinical outcome is associated with Amplicon Class for patients with stage I–III invasive breast cancer

Amplicon Class	Clinical outcome and number of patients (Total N = 33)
	NED or DNED	AWD or DOD
Class I	6 (4)	2 (0)
Class II	6 (5)	1 (0)
Class III	9 (9)	0
Class IV	3 (1)	6 (4)

NED: alive with no evidence of disease. DNED: died with no evidence of disease at least 24 months after diagnosis. AWD: Alive with breast cancer. DOD: died of breast cancer. NED and DNED were categorized as favorable outcome, and DOD and AWD as unfavorable for this analysis. Numbers in parentheses refer to the number of patients who received anthracycline-based therapy. The association between Amplicon class and clinical outcome is strongly significant, permutation based exact p-value = 0.007 from a chi-square test.

ISSN: 1756-8722